Patents by Inventor Karen Westerman
Karen Westerman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11701435Abstract: Provided are improved compositions and methods for achieving gene therapy in hematopoietic cells and hematopoietic precursor cells, including erythrocytes, erythroid progenitors, and embryonic stem cells. Also provided are improved gene therapy methods for treating hematopoietic-related disorders. Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.Type: GrantFiled: March 16, 2020Date of Patent: July 18, 2023Assignees: bluebird bio, Inc., Massachusetts Institute of TechnologyInventors: Philippe Louis Leboulch, Robert Pawliuk, Karen Westerman
-
Publication number: 20200368370Abstract: Provided are improved compositions and methods for achieving gene therapy in hematopoietic cells and hematopoietic precursor cells, including erythrocytes, erythroid progenitors, and embryonic stem cells. Also provided are improved gene therapy methods for treating hematopoietic-related disorders. Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.Type: ApplicationFiled: March 16, 2020Publication date: November 26, 2020Applicants: bluebird bio, Inc., Massachusetts Institute of TechnologyInventors: Philippe Louis LEBOULCH, Robert PAWLIUK, Karen WESTERMAN
-
Patent number: 10632212Abstract: The invention provides improved compositions and methods for achieving gene therapy in hematopoietic cells and hematopoietic precursor cells, including erythrocytes, erythroid progenitors, and embryonic stem cells. The invention further provides improved gene therapy methods for treating hematopoietic-related disorders. Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.Type: GrantFiled: September 13, 2018Date of Patent: April 28, 2020Assignees: bluebird bio, Inc., Massachusetts Institute of TechnologyInventors: Philippe Louis Leboulch, Robert Pawliuk, Karen Westerman
-
Publication number: 20190038775Abstract: Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.Type: ApplicationFiled: September 13, 2018Publication date: February 7, 2019Applicants: bluebird bio, Inc., Massachusetts Institute of TechnologyInventors: Philippe Louis Leboulch, Robert Pawliuk, Karen Westerman
-
Patent number: 10105451Abstract: The invention provides improved compositions and methods for achieving gene therapy in hematopoietic cells and hematopoietic precursor cells, including erythrocytes, erythroid progenitors, and embryonic stem cells. The invention further provides improved gene therapy methods for treating hematopoietic-related disorders. Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.Type: GrantFiled: April 29, 2015Date of Patent: October 23, 2018Assignees: bluebird bio, Inc., Massachusetts Institute of TechnologyInventors: Philippe Louis Leboulch, Robert Pawliuk, Karen Westerman
-
Publication number: 20160022839Abstract: Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.Type: ApplicationFiled: April 29, 2015Publication date: January 28, 2016Inventors: Philippe Louis LEBOULCH, Robert PAWLIUK, Karen WESTERMAN
-
Patent number: 9068199Abstract: The invention provides improved compositions and methods for achieving gene therapy in hematopoietic cells and hematopoietic precursor cells, including erythrocytes, erythroid progenitors, and embryonic stem cells. The invention further provides improved gene therapy methods for treating hematopoietic-related disorders. Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.Type: GrantFiled: September 23, 2011Date of Patent: June 30, 2015Assignees: Bluebird Bio, Inc., Massachusetts Institute of TechnologyInventors: Philippe Leboulch, Robert Pawliuk, Karen Westerman
-
Publication number: 20120009161Abstract: Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.Type: ApplicationFiled: September 23, 2011Publication date: January 12, 2012Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, BLUEBIRD BIO, INC.Inventors: Philippe LEBOULCH, Robert PAWLIUK, Karen WESTERMAN
-
Publication number: 20110274669Abstract: Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.Type: ApplicationFiled: December 22, 2010Publication date: November 10, 2011Inventors: Philippe LEBOULCH, Robert PAWLIUK, Karen WESTERMAN
-
Patent number: 8034620Abstract: Novel packaging cell lines which produce recombinant retrovirus, free of detectable helper-virus are disclosed. Also disclosed are methods of making the cell lines and methods of producing recombinant retroviruses from the cell lines. Retroviruses produced by the cell lines include lentiviruses, such as HIV, capable of transfering heterologous DNA to a wide range of non-dividing cells. The packaging cells contain at least three vectors which collectively encode retroviral gag, pol, and env proteins, wherein the gag and pol genes are separated, in part, onto two or more different vectors. This is made possible by fusing Vpr or Vpx to pol proteins separated from gag so that the proteins are targeted to assembling virions. Among other advantages, the packaging cells provide the benefit of increased safety when used in human gene therapy by virtually eliminating the possibility of molecular recombination leading to production of replication competent helper virus.Type: GrantFiled: November 9, 2007Date of Patent: October 11, 2011Assignee: Bluebird Bio, Inc.Inventors: Philippe Leboulch, Karen Westerman
-
Patent number: 7901671Abstract: The invention provides improved compositions and methods for achieving gene therapy in hematopoietic cells and hematopoietic precursor cells, including erythrocytes, erythroid progenitors, and embryonic stem cells. The invention further provides improved gene therapy methods for treating hematopoietic-related disorders. Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.Type: GrantFiled: June 9, 2005Date of Patent: March 8, 2011Assignee: bluebird bio, Inc.Inventors: Philippe Leboulch, Robert Pawliuk, Karen Westerman
-
Publication number: 20080187997Abstract: Novel packaging cell lines which produce recombinant retrovirus, free of detectable helper-virus are disclosed. Also disclosed are methods of making the cell lines and methods of producing recombinant retroviruses from the cell lines. Retroviruses produced by the cell lines include lentiviruses, such as HIV, capable of transferring heterologous DNA to a wide range of non-dividing cells. The packaging cells contain at least three vectors which collectively encode retroviral gag, pol, and env proteins, wherein the gag and pol genes are separated, in part, onto two or more different vectors. This is made possible by fusing Vpr or Vpx to pol proteins separated from gag so that the proteins are targeted to assembling virions. Among other advantages, the packaging cells provide the benefit of increased safety when used in human gene therapy by virtually eliminating the possibility of molecular recombination leading to production of replication-competant helper virus.Type: ApplicationFiled: November 9, 2007Publication date: August 7, 2008Applicant: Genetix Pharmaceuticals, Inc.Inventors: Philippe Leboulch, Karen Westerman
-
Patent number: 7311907Abstract: Novel packaging cell lines which produce recombinant retrovirus, free of detectable helper-virus are disclosed. Also disclosed are methods of making the cell lines and methods of producing recombinant retroviruses from the cell lines. Retroviruses produced by the cell lines include lentiviruses, such as HIV, capable of transfering heterologous DNA to a wide range of non-dividing cells. The packaging cells contain at least three vectors which collectively encode retroviral gag, pol, and env proteins, wherein the gag and pol genes are separated, in part, onto two or more different vectors. This is made possible by fusing Vpr or Vpx to pol proteins separated from gag so that the proteins are targeted to assembling virions. Among other advantages, the packaging cells provide the benefit of increased safety when used in human gene therapy by virtually eliminating the possibility of molecular recombination leading to production of replication competent helper virus.Type: GrantFiled: April 5, 2005Date of Patent: December 25, 2007Assignee: Genetix Pharmaceuticals, Inc.Inventors: Philippe Leboulch, Karen Westerman
-
Publication number: 20060057725Abstract: Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.Type: ApplicationFiled: June 9, 2005Publication date: March 16, 2006Applicants: Genetix Pharmaceuticals, Inc., MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Philippe Leboulch, Robert Pawliuk, Karen Westerman
-
Patent number: 6955919Abstract: Novel packaging cell lines which produce recombinant retrovirus, free of detectable helper-virus are disclosed. Also disclosed are methods of making the cell lines and methods of producing recombinant retroviruses from the cell lines. Retroviruses produced by the cell lines include lentiviruses, such as HIV, capable of transfering heterologous DNA to a wide range of non-dividing cells. The packaging cells contain at least three vectors which collectively encode retroviral gag, pol, and env proteins, wherein the gag and pol genes are separated, in part, onto two or more different vectors. This is made possible by fusing Vpr or Vpx to pol proteins separated from gag so that the proteins are targeted to assembling virions. Among other advantages, the packaging cells provide the benefit of increased safety when used in human gene therapy by virtually eliminating the possibility of molecular recombination leading to production of replication-competant helper virus.Type: GrantFiled: April 1, 2002Date of Patent: October 18, 2005Assignee: Genetix Pharmaceuticals, Inc.Inventors: Philippe Leboulch, Karen Westerman
-
Publication number: 20050170507Abstract: Novel packaging cell lines which produce recombinant retrovirus, free of detectable helper-virus are disclosed. Also disclosed are methods of making the cell lines and methods of producing recombinant retroviruses from the cell lines. Retroviruses produced by the cell lines include lentiviruses, such as HIV, capable of transfering heterologous DNA to a wide range of non-dividing cells. The packaging cells contain at least three vectors which collectively encode retroviral gag, pol, and env proteins, wherein the gag and pol genes are separated, in part, onto two or more different vectors. This is made possible by fusing Vpr or Vpx to pol proteins separated from gag so that the proteins are targeted to assembling virions. Among other advantages, the packaging cells provide the benefit of increased safety when used in human gene therapy by virtually eliminating the possibility of molecular recombination leading to production of replication-competant helper virus.Type: ApplicationFiled: April 5, 2005Publication date: August 4, 2005Applicant: Genetix Pharmaceuticals, Inc.Inventors: Philippe Leboulch, Karen Westerman
-
Publication number: 20030039636Abstract: Novel retroviral LTRs are disclosed for use in lentiviral gene therapy vectors. The R region of the LTR is derived from a lentivirus, but lacks all or a portion of the lentiviral TAR sequence to increase the safety of the gene therapy vector. The TAR sequence can be replaced by comparable sequences from the R region from a non-lentiviral retrovirus, thereby generating a hybrid lentiviral/non-lentiviral R region which lacks TAR. Also disclosed are gene therapy vectors including the LTRs and methods of using the vectors in lentiviral-based gene therapy.Type: ApplicationFiled: May 1, 2002Publication date: February 27, 2003Applicant: Genetix Pharmaceuticals, Inc.Inventors: Philippe Leboulch, Karen Westerman
-
Publication number: 20020168346Abstract: Novel packaging cell lines which produce recombinant retrovirus, free of detectable helper-virus are disclosed. Also disclosed are methods of making the cell lines and methods of producing recombinant retroviruses from the cell lines. Retroviruses produced by the cell lines include lentiviruses, such as HIV, capable of transfering heterologous DNA to a wide range of non-dividing cells. The packaging cells contain at least three vectors which collectively encode retroviral gag, pol, and env proteins, wherein the gag and pol genes are separated, in part, onto two or more different vectors. This is made possible by fusing Vpr or Vpx to pol proteins separated from gag so that the proteins are targeted to assembling virions. Among other advantages, the packaging cells provide the benefit of increased safety when used in human gene therapy by virtually eliminating the possibility of molecular recombination leading to production of replication-competant helper virus.Type: ApplicationFiled: April 1, 2002Publication date: November 14, 2002Applicant: Genetix Pharmaceuticals, Inc.Inventors: Philippe Leboulch, Karen Westerman
-
Patent number: 6365150Abstract: Novel packaging cell lines which produce recombinant retrovirus, free of detectable helper-virus are disclosed. Also disclosed are methods of making the cell lines and methods of producing recombinant retroviruses from the cell lines. Retroviruses produced by the cell lines include lentiviruses, such as HIV, capable of transfering heterologous DNA to a wide range of non-dividing cells. The packaging cells contain at least three vectors which collectively encode retroviral gag, pol, and env proteins, wherein the gag and pol genes are separated, in part, onto two or more different vectors. This is made possible by fusing Vpr or Vpx to pol proteins separated from gag so that the proteins are targeted to assembling virions. Among other advantages, the packaging cells provide the benefit of increased safety when used in human gene therapy by virtually eliminating the possibility of molecular recombination leading to production of replication-competant helper virus.Type: GrantFiled: May 13, 1999Date of Patent: April 2, 2002Assignee: Genetix Pharmaceuticals, Inc.Inventors: Philippe Leboulch, Karen Westerman
-
Patent number: 5928914Abstract: Methods and compositions for transforming cells, resulting in efficient and stable site-specific integration of transgenes, are disclosed. Transformation is achieved by introducing into a cell an acceptor vector, preferably a retroviral vector, which integrates into the genome of the cell. The acceptor vector comprises two incompatible lox sequences, L1 and L2. A donor vector is then introduced into the cell comprising a transgene flanked by the same L1 and L2 sequences. Stable gene transfer is initiated by contacting the lox L1 and L2 sequences with Cre recombinase.Type: GrantFiled: November 5, 1996Date of Patent: July 27, 1999Assignees: Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, Massachusetts Institute of TechnologyInventors: Philippe Leboulch, Eric Bouhassira, Karen Westerman, Ken Julian Takekoshi